NEW POSSIBILITIES OF MILD BRONCHIAL ASTHMA THERAPY

In the bronchial asthma structure the mild form of the disease takes the leading place: from 50 to 75% of patients suffer from mild asthma. Modern diagnostics of disease in these patients and adequate therapy allow preventing the disease progress. This article discusses issues of determination of the bronchial asthma gravity, incidence rate, disease burden and standard approaches to therapy of the mild bronchial asthma. Particular attention is given to a new possibility of therapy of mild asthma in adult patients with the help of the combined drug Salbutamol/Beclomethazone represented in the form of an aerosol inhaler and intended for arrest of symptoms and permanent therapy of bronchial asthma and chronic obstructive pulmonary disease in adults from the age of 18. Use of fixed combination Salbutamol/Beclomethazone in the regime “on demand” in adult patients with mild bronchial asthma leads to increase of the time to the first exacerbation and reduction of the disease exacerbations, at the same time it is accompanied by the minimum cumulative dosage of the inhalation corticosteroid and allows overcoming the low commitment of patients to therapy by inhalation corticosteroids